Publications

Show Filters

Searches all publications.

Search Fulltext

Publications

Section

Select publication to see the relevant sections.

Publication Date

    E.g., 2018-11-19
    E.g., 2018-11-19

Articles

Pages

173760 items
11:45 AM, Nov 16, 2018  |  BC Week In Review | Company News  |  Other News

Gyroscope-led consortium gets UK funding for cost-effective manufacture of AAV gene therapies

A consortium led by retinal gene therapy company Gyroscope Therapeutics Ltd. (Stevenage, U.K.) received a two-year, £1.1 million ($1.4 million) award from Innovate UK to develop a manufacturing platform for production of adeno-associated virus (AAV)...
11:27 AM, Nov 16, 2018  |  BC Week In Review | WIR Deals New Deals

Boehringer, Epizyme to develop small molecules against epigenetic cancer targets

Boehringer Ingelheim GmbH (Ingelheim, Germany) partnered with Epizyme Inc. (NASDAQ:EPZM) to develop small molecule inhibitors of two undisclosed epigenetic cancer targets in the helicase and histone acetyltransferase (HAT) families. The companies plan to focus on lung...
11:14 AM, Nov 16, 2018  |  BC Week In Review | Financial News  |  Completed Offerings

V-Bio, Gimv lead €37M Camel-IDS series A

Camelid-derived antibody company Camel-IDS N.V. (Brussels, Belgium) raised €37 million ($41.7 million) in a series A round Nov. 15 to support Phase II trials of lead brain metastatic breast cancer candidate, CAM-H2. V-Bio Ventures and...
11:13 AM, Nov 16, 2018  |  BC Week In Review | Company News  |  Deals

Sobi springboards U.S. growth in deal for AZ's Synagis

Swedish Orphan Biovitrum AB (SSE:SOBI) obtained U.S. rights to commercialize infectious disease drug Synagis palivizumab from AstraZeneca plc (LSE:AZN; NYSE:AZN) for $1.5 billion up front. Sobi called the deal, which also includes profit sharing with...
10:57 AM, Nov 16, 2018  |  BC Week In Review | Clinical News  |  Clinical Results

Blueprint reports 84% ORR for avapritinib in PDGFRα D842V-driven GIST

Blueprint Medicines Corp. (NASDAQ:BPMC) reported updated data from the Phase I NAVIGATOR trial showing that oral avapritinib led to an objective response rate (ORR) of 84% in 56 evaluable patients with PDGFRα D842V-driven advanced gastrointestinal...
10:57 AM, Nov 16, 2018  |  BC Week In Review | Company News  |  Other News

DeepMind's healthcare team joins Google

The DeepMind Technologies subsidiary of Alphabet Inc. (NASDAQ:GOOG) is merging its health team into Google Inc. following Google's announcement that David Feinberg will be joining the tech company to organize its healthcare efforts. Feinberg is...
10:56 AM, Nov 16, 2018  |  BC Week In Review | Company News  |  Sales & Marketing

ICER: asthma mAbs should be 50% cheaper for cost effectiveness

The Institute for Clinical and Economic Review (ICER) said the costs of five asthma mAbs would need to decrease by at least 50% to be cost effective in a final evidence report. ICER said that the...
10:50 AM, Nov 16, 2018  |  BC Week In Review | Company News  |  Other News

Google Brings Geisinger CEO on Board to Focus on Healthcare

Beyond a quick mention of Verily Life Sciences LLC and AI, Google Inc. is saying little about what it plans to do with its healthcare initiatives now that David Feinberg is leaving Geisinger Health System...
10:04 AM, Nov 16, 2018  |  BC Week In Review | Clinical News  |  Clinical Results

uniQure hemophilia B gene therapy leads to Factor IX activity level of 31% of normal

uniQure N.V. (NASDAQ:QURE) reported that all three patients who received hemophilia B gene therapy AMT-061 in a dose-confirmation Phase IIb trial achieved and sustained therapeutic levels of Factor IX activity. The company has started enrollment...
10:01 AM, Nov 16, 2018  |  BC Week In Review | Company News  |  Deals

Oxford BioDynamics partners EpiSwitch platform

Oxford BioDynamics plc (LSE:OBD) said it partnered with an undisclosed major U.S. pharma to use its EpiSwitch epigenetic biomarker platform to develop predictive biomarkers for immuno-oncology therapeutics. The company did not respond to inquiries. Oxford BioDynamics...

Pages